Lemaitre Vascular (LMAT) Enterprise Value (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Enterprise Value data on file, last reported at -$367.2 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$367.2 million, down 21.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$367.2 million (down 21.38% YoY), and the FY2025 annual result was -$359.1 million, down 19.82% from the prior year.
• Enterprise Value retreated to -$367.2 million in Q1 2026 per LMAT's latest filing, from -$359.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$70.9 million in Q1 2022 and troughed at -$367.2 million in Q1 2026.
• A 5-year average of -$177.6 million and a median of -$108.3 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 247.87% in 2022, then decreased 14.28% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$82.7 million in 2022, then slipped by 27.07% to -$105.1 million in 2023, then sank by 185.25% to -$299.7 million in 2024, then decreased by 19.82% to -$359.1 million in 2025, then decreased by 2.26% to -$367.2 million in 2026.
• Business Quant data shows LMAT's Enterprise Value at -$367.2 million in Q1 2026, -$359.1 million in Q4 2025, and -$343.1 million in Q3 2025.